MARKET NEWS

MeiraGTx Announces Acquisition of Vector Neurosciences
Sitryx Launches With $30 Million to Develop Disease-Modifying Therapeutics
BioCorRx Announces Preliminary Agreement With VDM Biochemicals
Acquisitions Bolster PCI’s Global Position for Speed-to-Market
Amicus Therapeutics Enters Research & Development Collaboration
Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases

  FEATURED EDITORIAL

  COMPANY PROFILE

Pharmaceutical formulators continue to strive to create market leading products with maximum efficacy, quality, and performance. However, the inability to achieve API solubility and stability are common day-to-day challenges for formulators. With the help from Croda’s superior quality and ultrahigh purity specialty line of excipients, formulators are able to surpass these barriers, making Croda the supplier of choice in the global pharmaceutical market. With products being manufactured at multiple sites throughout the world, we are able to provide local and consistent supply of one of the widest ranges of chemical specialties, surfactants, and high-purity lipids available to the pharmaceutical industry. Click here for more.

  EXCLUSIVE ONLINE CONTENT

Cartridge Filling: Combination of Features That Can Help Gain a Competitive Edge

Cartridge Filling: Combination of Features That Can Help Gain a Competitive Edge

By 2050, it is projected that the proportion of people aged 65 and older will be more than double that of children aged 5. This global phenomenon is also leading to an increasing number of people suffering from chronic diseases, such as diabetes and osteoporosis.

Pacific Biosciences Announces a New Paradigm in DNA Sequencing

Pacific Biosciences Announces a New Paradigm in DNA Sequencing

Pacific Biosciences of California, Inc. recently announced major enhancements to its Sequel System, including a new version (6.0) of its software, new consumable reagents (3.0) and a new SMRT Cell (1M v3).

Ziopharm & Precigen Redefine Relationships, Announce New License Agreement

Ziopharm & Precigen Redefine Relationships, Announce New License Agreement

Ziopharm Oncology, Inc. and Precigen, Inc. recently announced a new definitive license agreement to replace all existing agreements between the companies that will provide Ziopharm with certain exclusive and non-exclusive rights to technology controlled by Precigen, Inc.   

A New Generation of Ophthalmic Products With Pylote Eco-Friendly Protection Offers Improved Safety & Comfort for Patients

A New Generation of Ophthalmic Products With Pylote Eco-Friendly Protection Offers Improved Safety & Comfort for Patients

Like all pharmaceuticals, ophthalmic preparations are subject to microbiological contamination. Both ophthalmic solutions used for diagnostic and therapeutic purposes have been found to be contaminated by pathogenic bacteria with reported rates as high as 70%, associated with severe ocular infections such as keratitis and endophthalmitis.

  DRUG DEVELOPMENT DIRECT RESOURCES

Upcoming eNewsletter Features:

October 24 – Capsules
October 31 – Analytical Testing